drugset / Trial / NCT06125171
Tucidinostat Plus Apatinib for Advanced Osteosarcoma
Phase 2
Unknown
46 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
This phase II study was designed to assess the efficacy and safety of the combination of Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory osteosarcoma patients.
Timeline
- Start
- 2024-01
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Rivoceranib | Small molecule | 500 mg | — |
| Subject | Tucidinostat | Small molecule | 0.5 mg/kg | Oral |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |